Abstract: Poster Presentations |

Safety of Mometasone Furoate Dry Powder Inhaler and Comparison with Beclomethasone Dipropionate in Children with Asthma Previously Maintained on Inhaled Corticosteroids (ICS) FREE TO VIEW

Michael Noonan, MD*; Jonathan Corren, MD; Jeffrey Leflein, MD
Author and Funding Information

Allergy Associates Research, Portland, OR


Chest. 2004;126(4_MeetingAbstracts):912S. doi:10.1378/chest.126.4_MeetingAbstracts.912S
Text Size: A A A
Published online


PURPOSE:  To assess the long-term pediatric safety of mometasone furoate dry powder inhaler (MF-DPI) and compare it with that of beclomethasone dipropionate metered dose inhaler (BDP-MDI).

METHODS:  Children (N = 233) aged 4 –11 years were randomized to 52 weeks of treatment with MF-DPI 200 mcg qd AM, MF-DPI 100 mcg bid, or BDP-MDI 168 mcg bid. Subjects had used ICS daily for ≥ 30 days before the screening visit, and were on stable ICS doses for ≥ 2 weeks before screening. The primary safety variables were adverse events. Secondary safety variables included vital signs and physical examination.

RESULTS:  The incidences of treatment-emergent adverse events were similar in all three treatment groups. The most frequently reported adverse event was upper respiratory tract infection, reported by 47% to 51% of subjects. Most adverse events were considered unrelated to study drug, and those considered related to treatment were consistent with all treatment-emergent adverse events. The most frequently reported related adverse events were headache (MF-DPI 200 mcg qd AM, 8%; MF-DPI 100 mcg bid, 4%; BDP-MDI 168 mcg bid, 2%) and oral candidiasis (4% in each treatment group). No clinically relevant changes in laboratory values, vital signs, or physical examinations were noted in any treatment group.

CONCLUSION:  Both MF-DPI doses were well tolerated, with no unusual or unexpected adverse events or safety concerns, and had a similar adverse event profile to that of BDP-MDI 168 mcg bid.

CLINICAL IMPLICATIONS:  MF-DPI is a well-toleratd ICS for the treatment of pediatric asthma.

DISCLOSURE:  M. Noonan, Schering-Plough Research Institute

Wednesday, October 27, 2004

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543